Tezepelumab Granted Orphan Drug Status for Eosinophilic Esophagitis
Tezepelumab is a first-in-class human monoclonal antibody that works by blocking thymic stromal lymphopoietin.
Eosinophilic Esophagitis
Etrasimod Granted Orphan Drug Status for Eosinophilic Esophagitis
Etrasimod is an investigational, next generation, once-daily, oral, highly selective sphingosine 1-phosphate receptor modulator.
Budesonide Oral Suspension Improves Multiple Outcomes in Pediatric Eosinophilic Esophagitis
Budesonide oral suspension improved histologic, endoscopic, and both histologic and symptomatic outcomes in children with eosinophilic esophagitis compared with placebo.
Active Eosinophilic Esophagitis Associated With Increased Asthma Severity
Active eosinophilic esophagitis appears to be associated with lower lung function and increased asthma severity in children with comorbid asthma.
Increased Risk of Eosinophilic Esophagitis in Children With IBD
Researchers evaluated the potential predictive characteristics of eosinophilic esophagitis following IBD diagnosis in children.
MPR Weekly Dose Podcast Episode 62
Its been a long year, but the monumental efforts to achieve a COVID-19 vaccine are bearing some fruits, we about that, and also a fully at home diagnostic COVID test, as well as new findings related to glucosamine supplements and a novel treatment for eosinophilic esophagitis. And as ever, one final movie trivia ‘guess the quote’ to end the year!
Novel Budesonide Oral Suspension Gets Priority Review for Eosinophilic Esophagitis
The FDA has accepted for review the NDA and granted Priority Review to TAK-721 (budesonide oral suspension) for the treatment of eosinophilic esophagitis.
Guidelines Issued for Managing Eosinophilic Esophagitis
Topical glucocorticosteroids recommended over no treatment.
Recall: NDMA Identified in Mylan’s Nizatidine Capsules
Mylan has announced a recall of 3 lots of Nizatidine Capsules as the products were manufactured with an active pharmaceutical ingredient (API) that contained trace amounts of N-nitrosodimethylamine (NDMA), a probable human carcinogen.
Successful Treatment of Long-Term Eosinophilic Esophagitis With JAK Inhibitor
Several treatments were attempted but failed to manage the patient’s conditions, including proton pump inhibitors, topical steroids, a restricted diet, and infliximab (3 doses) for arthritis.
